Clinical Trial Update: Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 clinical trial evaluating LB1410 in combination with lenvatinib, with or without LB4330, for advanced recurrent/metastatic cervical cancer; th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• LB1410
• LB4330
• Lenvatinib (lenvatinib)

Snippet

Sponsor: L & L Bio Co., Ltd., Ningbo, China | Conditions: Cervical Cancer | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING